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ABSTRACT 
 This prospective study evaluates whether CMV-seropositive (R+) transplant patients 
with pretransplant CD8+IFNG+ T-cell response to cytomegalovirus (CMV) (CD8+IFNG+ 
response) can spontaneously clear the CMV viral load without requiring treatment. A total of 
104 transplant patients (kidney/liver) with pretransplant CD8+IFNG+ response were 
evaluable. This response was determined using QuantiFERON-CMV assay. The incidence of 
CMV replication and disease was 45.2% (47/104) and 6.7% (7/104), respectively. Of the total 
patients, 77.9% (81/104) did not require antiviral treatment, either because they did not have 
CMV replication (n = 57) or because they had asymptomatic CMV replication that could be 
spontaneously cleared (n = 24). Both situations are likely related to the presence of 
CD8+IFNG+ response to CMV, which has a key role in controlling CMV infection. However, 
22.1% of the patients (23/104) received antiviral treatment, although only 7 of them did so 
because they had symptomatic CMV replication. These patients developed symptoms in spite 
of having pretransplant CD8+IFNG+ response, thus suggesting that other immunological 
parameters might be involved, such as a dysfunctional CD4+ response, or that they might 
have become QFNon-reactive due to the immunosuppression. In conclusion, around at least 80% 
of R+ patients with pretransplant CD8+IFNG+ response to CMV did not require antiviral 
treatment, although this percentage might be underestimated. Nevertheless, we recommend 
performing an additional CD8+IFNG+ response determination at posttransplant time to 
provide more reliable information regarding the patients who will be able to spontaneously 
clear the viremia. 
 
KEYWORDS: solid organ transplantation, cytomegalovirus infection, T-cell response, 
QuantiFERON-CMV assay, interferon-gamma  
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1. INTRODUCTION 
CMV infection is a well-known complication after solid organ transplantation (SOT) 
and two major strategies are commonly used for the prevention of CMV: prophylaxis or pre-
emptive therapy (Kotton et al. 2013; Torre-Cisneros et al. 2016). Pre-emptive therapy is 
mainly used in low-risk patients once viral replication reaches a certain threshold and 
optimally before the development of symptoms. This strategy involves the virological 
monitoring of CMV infection, which is cumbersome for patients and costly in terms of 
material and human resources. Low-risk patients include CMV-seropositive patients, since 
they are expected to have specific immune response against this virus and a low probability of 
developing CMV disease.  
Both CMV-specific humoral and cellular immunity have been shown to play a 
relevant role against CMV infection. However, to stratify the risk in transplant candidates 
awaiting transplantation, only recipient CMV serology is considered. Recent studies have 
reported that the presence of IFNG+ CMV-specific CD8+ T-cell (CD8+IFNG+) response at 
pretransplant or posttransplant is associated with a lower risk of CMV infection (Bestard et al. 
2013; Cantisán et al. 2013; Kumar et al. 2009; López-Oliva et al. 2014; Manuel et al. 2013). 
By contrast, the lack of pretrasplant CD8+IFNG+ response in some CMV-seropositive 
patients has been reported as being associated with a higher risk of CMV replication after 
transplantation (Bestard et al. 2013; Cantisán et al. 2013; López-Oliva et al. 2014). According 
to this evidence, we hypothesize that transplant patients with pretransplant CD8+IFNG+ 
response should be able to spontaneously clear the CMV viral load without the need for 
antiviral treatment, thus reducing the need for pre-emptive treatment.  
The aim of the current study was to evaluate whether CMV-seropositive transplant 
patients who display CD8+IFNG+ response before transplantation are able to control 
replication and/or self-clear the viral load without requiring treatment.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
 
2. MATERIAL AND METHODS 
2.1. Study population and design  
This prospective study was carried out in eight centers of the Spanish Network for 
Research in Infectious Diseases (REIPI), in four centers of the Spanish Kidney Disease 
Network (RedInRen) and in one center of Sao Paulo, Brazil. Adult transplant candidates with 
pretransplant CD8+IFNG+ response to CMV, who were awaiting a kidney or liver transplant 
and who were not expected to receive antiviral prophylaxis with either ganciclovir or 
valganciclovir were eligible for the study. Tacrolimus-based immunosuppression protocols 
were as per the center-specific standard. We obtained approval from institutional review 
boards before initiation of enrollment at each center and informed consent from all 
participants. 
Patients were recruited from February 2013 to March 2016. CD8+IFNG+ response to 
CMV was assessed pretransplant, either when they were on the waiting list in the case of 
recipients who received a graft from a deceased donor or the day prior to transplantation for 
patients receiving a graft from living donors. Patients who received a graft were monitored for 
CMV replication for 6 months following transplantation. The protocol study established that 
pre-emptive strategy should not be initiated in patients with asymptomatic replication, but to 
start an observation phase in these patients where CMV load would be monitored at least 
weekly during the first two months, every two weeks until the third month, monthly until the 
sixth month after SOT and when clinically indicated. Antiviral treatment would be initiated 
only in the event that the patients developed symptoms, although the decision to initiate 
treatment was ultimately at the discretion of the treating physician based on the individualized 
evaluation of the patient (immunosuppression, general state, viral load kinetics, etc.). 
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Patients with CMV replication were classified as asymptomatic or as having CMV 
disease according to standard definitions (Torre-Cisneros et al. 2016).   
 
2.2. Determination of anti-CMV IgG antibodies and CMV viral load 
Serology testing for anti-CMV IgG was performed on all samples using the Diasorin 
chemoluminescence assay (Diasorin SA, Spain) as per manufacturer’s instructions. Titers 
< 12 U/mL were classified as negative. CMV load was determined in plasma by real time 
PCR using the technique implemented at each center. The detection limit was 137 IU/mL. 
Peak viral load was defined as the maximum viral load within the posttransplant period. 
The duration of CMV replication was calculated as the number of days from the first 
positive PCR to the first negative PCR. In patients with more than one episode, the total 
number of days of the different episodes was considered. 
 
2.3. QuantiFERON-CMV assay 
 CD8+IFNG+ response was assessed using the QuantiFERON-CMV® (QF) test 
(Qiagen, Germany) (Walker et al. 2007). In brief, 1 mL of heparinized whole blood was 
collected in three QF tubes containing no antigens (negative control) or a mix of 22 CMV 
peptides or phytohemagglutinin (positive control). The tubes were shaken vigorously and 
incubated for 16–24 hours at 37ºC. Supernatants were harvested and analyzed for IFNG level 
(IU/mL) by standard ELISA. The supernatants from all patients were shipped to our center 
and IFNG level was therefore analyzed in the same platform. The negative control response 
was subtracted from either the CMV antigen or mitogen tubes. According to the 
manufacturer’s instructions, a result was considered “Reactive” when the CMV antigen 
response was equal to or greater than 0.2 IU/mL of IFNG. A result was considered “Non-
reactive” when the CMV antigen response was lower than 0.2 IU/mL and the mitogen 
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response was higher than 0.5 IU/mL. A result was “Indeterminate” when the IFNG level was 
less than 0.2 IU/mL in the CMV antigen tube and less than 0.5 IU/mL in the mitogen tube. 
 
2.4. Study of CD8+ T-cell phenotype 
Peripheral blood mononuclear cells (PBMCs) were isolated and cryopreserved. At the 
time of analysis, 500,000 thawed PBMCs were incubated with fluorochrome-labeled 
antibodies to CD4 (Viogreen), CD8 (PE-Vio770), CD57 (Vioblue) and programmed cell 
death 1 (PD-1) (Viobright FITC) (all from Miltenty Biotec). Cell viability was analyzed using 
7-Amino Actinomycin D (7-AAD) (eBiosciences). After 30 min on ice in the dark, flow 
cytometry analysis was performed on a LSRFortessa SORP cytometer (Becton Dickinson). 
The resulting profiles were analyzed using FlowJo software. The expression of CD57 and PD-
1 were referred to on CD4+ or CD8+ T cells.  
 
2.5. Statistical analysis 
The statistical analysis was performed using PASW Statistics 18.0 software (IBM 
Corporation). The Chi-squared or Exact Tests were used to compare the distribution of 
categorical variables among the three groups. Quantitative data were analyzed with the 
nonparametric Kruskal-Wallis Test (three group comparisons) or Mann-Whitney U test (two 
group comparisons). A 2-sided p-value of 0.05 was considered statistically significant. 
 
3. RESULTS 
3.1. Patient characteristics 
A total of 104 R+ patients with pretransplant CD8+IFNG+ response to CMV (IFNG ≥ 
0.2 UI/mL), who were classified as QFReactive, were evaluable and completed the monitoring 
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phase. The clinical-demographic characteristics of these patients are shown in Table 1. Fifty-
one patients received a renal transplant and 53 patients received a liver transplant. Forty-seven 
patients received induction therapy, of which 45 received basiliximab and 2 received 
thymoglobulin. These two patients met the inclusion criteria since they did not receive 
prophylaxis with valganciclovir.  
 
3.2. Incidence and kinetics of CMV replication: self-resolved versus symptomatic 
patients 
  Within 6 months after transplantation, CMV replication occurred in 47 out of these 
104 patients (45.2%). Of the 47 patients with replication, 91.5% (43/47) experienced only one 
episode and 8.5% (4/47) had more than one episode. The total median duration of CMV 
replication was 30 days (range, 4–415 days). The minimum duration of replication was 4 days 
as one patient died 22 days after transplantation. The median peak viral load was 1980 UI/mL 
(range, 150–131794 UI/mL). The patients developed CMV replication at a median of 34 days 
after SOT (range, 16–162 days).   
The incidence of CMV disease was 6.7% (7/104) (3 viral syndrome and 4 end-organ 
disease). Two patients had gastrointestinal disease, one had hepatitis and one had respiratory 
disease. 
 The study flow diagram is shown in Figure 1. Of the 104 patients, 77.9% (81/104) did 
not require anti-CMV treatment because either they did not have CMV replication (n = 57) or 
because they had asymptomatic CMV replication that could be spontaneously cleared 
(n = 24), which represents 51.1% (24/47) of the patients with CMV replication. These 24 
patients developed CMV replication at a median time of 41.5 days (range, 22–162 days) and 
the total duration of the episodes was 28 days (range, 4–80 days).  The minimum duration of 
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replication in this group was 4 days as one patient died 22 days after transplantation. The 
median peak viral load was 483.0 UI/mL (range, 150–5134 UI/mL). Figure 2 shows the 
kinetics of self-resolved infection in the four patients with a viral load higher than 2000 
UI/mL, including the patient with the highest viral load that could be spontaneously cleared 
(5134 UI/mL). 
 In contrast, 22.1% of the patients (23/104) received antiviral treatment, although only 
7 of them (7/23; 30.4%) did so because they had symptomatic CMV replication. These 
symptomatic patients developed CMV replication earlier than the patients with spontaneous 
clearance (29 vs. 41.5 days; p = 0.025) and CMV replicated longer, although the differences 
were not statistically significant (42 vs. 28 days; p = 0.357). The median peak viral load at 
treatment was 4576 UI/mL (range, 2310–131794 UI/mL), much higher than in self-resolved 
patients. The remaining 16 patients received treatment according to their physicians’ 
decisions mainly based on an elevated viral load (median 3993 UI/mL) although they were 
asymptomatic. However, it is important to note the high variability in the threshold for 
initiation of pre-emptive therapy in these asymptomatic patients, which ranged from 335 to 
22832 UI/mL (Figure 3). Nine out of these 16 patients initiated antiviral treatment at a viral 
load below 5000 UI/mL and therefore received treatment at a viral load that could be 
spontaneously cleared in the self-resolved group. 
 
3.3. Comparison of non-replication, self-resolved and symptomatic patients  
We then analyzed whether the self-resolved patients had some differential 
characteristics compared to the other groups. For this purpose, the 16 asymptomatic patients 
who received antiviral treatment were excluded in order to prevent a possible bias due to the 
overlapping of these patients with the self-resolved patients. Therefore, the three groups we 
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compared were: non-replication (n = 57), self-resolved (SR) replication (n = 24) and 
symptomatic replication (n = 7) (Table 2).  
The median age of patients did not significantly differ among the three groups. When 
age was used as a categorical variable (patients younger and older than 57 years), we 
observed that patients with CMV replication were older than those without replication, with 
patients showing symptomatic replication being the oldest. We also observed that all the 
patients who could not control the replication had received an organ from a D+ donor. 
However, the only parameter that significantly differed among the three groups was the 
presence of the HLA-A2 allele. Although patients with CMV replication had an increased 
frequency of this allele compared to non-replication patients (58.1% vs 28.1%; Chi-square 
test p=0.006), the frequency of HLA-A2 allele was higher in the group of patients who were 
able to spontaneously clear the replication compared to the other two groups. Therefore, 
62.5% of the patients (15/24) in the SR group had the HLA-A2 allele, whereas the 
frequencies of this allele were 28.1% (16/57) and 42.9% (3/7) in the non-replication and 
symptomatic groups, respectively.  
 
3.4. Relationship between the level of IFNG secretion and spontaneous clearance of 
CMV replication  
 We then investigated whether there was any correlation between the level of IFNG 
released and spontaneous clearance. We found no significant differences among the three 
groups (Figure 4). The most relevant finding was that, unexpectedly, the median IFNG level 
was lower in the non-replication group than in the two groups with replication, with the level 
being very similar in the SR and symptomatic groups (11.0 UI/mL for the non-replication 
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group vs. 23.6 UI/mL and 28.4 UI/mL for the SR and symptomatic replication groups, 
respectively).  
 Moreover, we did not observe any association between pretransplant IFNG level and 
peak viral load and the onset of CMV replication in patients with CMV replication.  
 
3.5. Relationship between the frequency of highly experienced T cells and the self-
resolution of CMV replication  
In order to investigate whether the differentiation status of T cells before 
transplantation was related to the ability to clear the CMV viral load, we also compared the 
frequency of experienced T cells among the three groups. To do so, we compared the 
frequency of CD4+CD57+, CD4+PD-1+, CD8+CD57+ and CD8+PD-1+ subpopulations 
among the three categories. Phenotypic analysis could only be performed in a subgroup of 58 
patients (41 non-replication, 14 SR replication and 3 symptomatic replication) since 
peripheral blood mononuclear cells were available only in this group. The gating strategy is 
shown in the Figure 5. 
We found significant differences only in the frequencies of CD4+CD57+ and 
CD4+PD-1+ cells (Figure 6). Patients with self-resolved replication had a higher frequency of 
CD4+CD57+ and CD4+PD-1+ T cells than the non-replication and symptomatic replication 
patients. In particular, the median percentage of the CD4+CD57+ subset was 6.3% in the SR 
replication patients, whereas it was 3.2% and 2.2% in patients with no replication and in the 
symptomatic replication group, respectively. Regarding the CD4+PD-1+ subset, the median 
percentage was 18.5% in the SR replication group compared to 14.9% in the non-replication 
group and 8.4% in the symptomatic replication group. The median frequency of CD8+CD57+ 
T cells was also higher in the SR replication group than in the other groups, although the 
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differences did not reach statistical significance, which might be related to the small sample 
size.  
 
 
4. DISCUSSION 
In this study we analyze the spontaneous clearance of CMV replication in R+ kidney 
or liver transplant patients with pretransplant CD8+IFNG+ response to CMV. The main result 
is that the majority of the patients, around 80%, did not require antiviral treatment either 
because they did not have CMV replication or they had asymptomatic replication that could 
be spontaneously cleared, which accounts for half of the patients with CMV replication. Both 
situations are likely related to the fact that these patients had CD8+IFNG+ response to CMV 
before transplantation, which maintains CMV under control and prevents the development of 
symptoms. This result is in line with those reported previously by other authors, who have 
indicated the key role of CD8+ T cells in the self-resolution of CMV reactivation 
(Benmarzouk-Hidalgo et al 2011; Kumar et al. 2017; Lisboa et al. 2012). In this regard, 
Benmarzouk-Hidalgo et al. (2011) observed that the acquisition of CMV-specific immune 
response in D+R- transplant patients was associated with the clearance of 97.8% of the CMV 
replication episodes without the administration of valganciclovir. In the same line, Lisboa et 
al. (2012) reported that CD8+ T-cell response assessment shortly after the onset of CMV 
viremia in solid organ transplant patients can identify which patients will spontaneously clear 
the virus. In addition, a recently published interventional study has reported that cell-mediated 
immunity against CMV can be performed in real time to guide clinical decisions to treat 
patients or not with antiviral therapy (Kumar et al. 2017). 
However, we also observed that the pretransplant IFNG level does not explain why 
some patients with CMV replication can self-resolve the infection while others cannot, since 
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both groups have very similar median levels. We analyzed whether other parameters are 
involved and found significant results with the HLA-A2 allele. We observed that the HLA-A2 
allele is related to a higher efficiency in self-controlling the viremia, which might be 
associated with the immunodominance of the HLA-A2-restricted pp65 complex and/or with 
an increased frequency of highly efficient polyfunctional T cells (Elkington et al. 2003; 
Snyder et al. 2016).  
In the present work, however, some patients received antiviral treatment because they 
had developed symptomatic replication in spite of having pretransplant CD8+IFNG+ 
response. There are several possible explanations for this. It might be related to an inefficient 
CD4+ response against CMV, as has been reported by Gabanti et al. (2014). These authors 
found that the presence of functional CMV-specific CD8+ T cells in seropositive transplant 
patients is not enough to confer protection against CMV disease and observed complete 
protection against CMV only when CMV-specific CD4+ T cells reconstitute their function 
and provide help to CD8+ T cells (Gabanti et al. 2014). The relevance of CD4+ T cells in the 
control of CMV infection has been widely reported (Drylewicz et al. 2016; Harari et al. 2004; 
Sester et al. 2001).  Therefore, it would be reasonable to think that the patients with 
symptomatic replication had pretransplant CD8+IFNG+ response but may have had an 
insufficient CD4+ response. Although we do not have functional information about CD4+ T 
cells since we used the QuantiFERON-CMV assay, we have phenotypic data supporting this 
idea. The fact that the frequency of CD4+CD57+ and CD4+PD-1+ subpopulations was higher 
in the patients who self-resolved the infection than in the other patients suggests that these 
highly experienced CD4+ T cells might contribute to a more efficient response against CMV 
(Espinosa et al. 2016; Pera et al. 2017).  
Another explanation could be that some pretransplant QFReactive patients might 
become QFNon-reactive after transplantation due to the T-cell dysfunctionality induced by 
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immunosuppression (Egli et al. 2013; Engstrand et al. 2003). If this were the case, the 
assessment of a single CD8+IFNG+ response determination before transplantation would not 
accurately identify patients at low risk of CMV disease. Although this result seems to be in 
contradiction with what we previously reported (Cantisán et al. 2013), it might be explained 
by differences in the characteristics of the patients included in both studies. Therefore, we 
now suggest that a second CD8+IFNG+ response determination should be additionally 
performed after transplantation, when patients are under immunosuppression. Alternatively, 
the lack of protection against CMV disease in patients with pretransplant CD8+IFNG+ 
response could be related to the absence of secretion of other relevant cytokines, which are 
not analyzed by the QuantiFERON-CMV assay (Ciuffreda et al. 2008; Darrah et al. 2007; 
Gibson et al. 2015; Snyder et al. 2016). 
Most of the patients who received antiviral treatment were asymptomatic but received 
antiviral treatment according to their physicians’ recommendation. The high variation in the 
viral load threshold at which treatment was initiated indicates the need for standardization 
(Kotton et al. 2013; Torre-Cisneros et al. 2016). Some patients received treatment at a viral 
load that could be spontaneously cleared in the self-resolved group, so it would be reasonable 
to think that the use of antiviral treatment in these patients might have been avoided, thus 
increasing the number of patients who did not need antiviral treatment (90 out of 104, 86.5%) 
and eliminating the potential harmful side effects of the anti-CMV drugs (Billar et al. 2016; 
Reusser et al. 2002).  
Our study has several limitations. The main limitation is that initiation of antiviral 
treatment was subject to the judgment of the attending physician, which led to a high 
variability in the viral load threshold at which it was initiated and the likelihood of 
underestimating the number of patients who are able to self-resolve the CMV replication. 
Another limitation was that the QuantiFERON-CMV assay only provides information about 
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IFNG secretion by CMV-specific CD8+ T-cell response but not about other cytokines and 
immune cells. In addition, we do not have information about IFNG secretion after 
transplantation when patients are under immunosuppression.  
In conclusion, our results demonstrate that, at least, around 80% of R+ kidney/liver 
transplanted patients with pretransplant CD8+IFNG+ response do not need antiviral treatment 
although we are aware that the study design does not allow us to establish a causal 
relationship between pretransplant CD8+IFNG+ response and the self-resolution of CMV 
replication. We acknowledge the limitation of the pretransplant strategy, since a few patients 
developed symptomatic replication in spite of being QFReactive before transplantation. This 
observation indicates that a single pretransplant QF determination might not be sufficiently 
informative for the risk of CMV disease since the effect of immunosuppressant drugs is not 
considered. Therefore, other strategies might be investigated, such as: i) performing an 
additional posttransplant QF assay, which would be subjected to a cost-effectiveness analysis; 
ii) substituting the pretransplant QF for an early posstransplant test or iii) a pretransplant QF 
assay followed by a posttransplant assay at the time that patients have a positive viral load. 
Furthermore, other immunological parameters such as HLA alleles or the frequency of highly 
experienced T cells seem to be also involved.  
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FIGURE LEGENDS 
Figure 1. Flow diagram of the study. 
 
Figure 2. Kinetics of CMV viral load in four representative patients with self-resolved CMV 
replication whose peak viral loads were higher than 2000 UI/mL. 
 
Figure 3. Individual CMV viral load at initiation of antiviral treatment in patients who 
received antiviral treatment in spite of having asymptomatic CMV replication (n = 16).  
 
Figure 4. Comparison of pretransplant IFNG secreted by CMV-specific CD8+ T cells in non-
replication (n = 57), self-resolved (n = 24) and symptomatic (n = 7) patients. IFNG release 
was assessed using the QuantiFERON-CMV assay. Horizontal lines represent median values. 
 
Figure 5. Gating strategy to analyze the frequency of highly experienced CD4+ and CD8+ T 
cells (CD4+CD57+, CD4+PD-1+, CD8+CD57+ and CD8+PD-1+ T-cell subsets). 
 
Figure 6. Percentage (%) of CD4+ and CD8+ subsets and highly experienced CD4+CD57+, 
CD4+PD-1+, CD8+CD57+ and CD8+PD-1+ T-cell subsets in a subgroup of patients (non-
replication, n = 41; self-resolved, n = 14 and symptomatic patients, n = 3). Horizontal lines 
represent median values. 
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Table 1. Distribution of demographic characteristics. 
 
Parameters All participants 
(n = 104) 
Age, median (range) 57 (26-76) 
Age, n (%)a  
< 57 53 (50.9) 
> 57 51 (49.0) 
HLA-A2 allele, n (%)  
No 65 (62.5) 
Yes 39 (37.5) 
Gender, n (%)  
Female 30 (28.8) 
Male 74 (71.1) 
Donor CMV serology, n (%)b  
D- 16 (15.4) 
D+ 83 (79.8) 
Use of mTOR, n (%)  
No 83 (79.8) 
Yes 21 (20.2) 
Transplanted organ, n (%)  
Kidney  51 (49.0) 
Liver 53 (50.9) 
Rejection, n (%)  
No  86 (82.7) 
Yes 18 (17.3) 
Type of donor, n (%)  
Living 26 (25.0) 
Deceased  78 (75.0) 
Induction therapy, n (%)  
No  57 (54.8) 
Basiliximab 45 (43.2) 
Thymoglobulin 2 (1.9) 
a
 Age is shown as below and above the median value. 
b Some missing values. 
Abbreviations: mTOR, mammalian target of rapamycin; D, 
donor. 
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Table 2. Characteristics of the sample population of 88 patients and comparison of the 
distribution of these characteristics among the non-replication, self-resolved and symptomatic 
subgroups. 
Parameters All 
participants 
(n = 88) 
Non-
replication 
(n = 57) 
SR 
replication 
(n = 24) 
Symptomatic 
replication 
(n = 7) 
pa 
Age, median (range) 57 (26-70) 54 (26-70) 59.5 (29-69) 59 (38-70) 0.125 
Ageb      
<57 46 (52.3) 35 (61.4) 9 (37.5) 2 (28.6) 0.059 
>57 42 (47.7) 22 (38.6) 15 (62.5) 5 (71.4)  
HLA-A2 allele      
No 54 (61.4) 41 (71.9) 9 (37.5) 4 (57.1) 0.012 
Yes 34 (38.6) 16 (28.1) 15 (62.5) 3 (42.9)  
Gender      
Female 25 (28.4) 16 (28.1) 8 (33.3) 1 (14.3) 0.617 
Male 63 (71.6) 41 (71.9) 16 (66.7) 6 (85.7)  
Donor CMV 
serologyc 
     
D- 16 (18.2) 12 (21.8) 4 (18.2) - 0.451 
D+ 67 (76.1) 43 (78.2) 18 (81.8) 6 (85.7)  
Use of mTOR      
No 69 (78.4) 44 (77.2) 21 (87.5) 4 (57.1) 0.196 
Yes 19 (21.6) 13 (22.8) 3 (12.5) 3 (42.9)  
Transplanted organ      
Kidney  44 (50.0) 29 (50.9) 11 (45.8) 4 (57.1) 0.892 
Liver 44 (50.0) 28 (49.1) 13 (54.2) 3 (42.9)  
Rejection      
No  74 (84.1) 47 (82.5) 22 (91.7) 5 (71.4) 0.385 
Yes 14 (15.9) 10 (17.5) 2 (8.3) 2 (28.6)  
Type of donor      
Living 20 (22.7) 14 (24.6) 4 (16.7) 2 (28.6) 0.714 
Deceased  68 (77.3) 43 (75.4) 20 (83.3) 5 (71.4)  
Induction therapy      
No  51 (58.0) 35 (61.4) 12 (50.0) 4 (57.1) 0.256 
Basiliximab 35 (39.8) 22 (38.6) 10 (41.7) 3 (42.9)  
Thymoglobulin 2 (2.3) 0 2 (8.3) -  
Data represent the number of patients. In parentheses, the frequency (%) with respect to the total 
number of patients in each column.  
a
 The non-replication, self-resolved (SR) and symptomatic subgroups were compared using the exact 
chi-squared test. For quantitative age, the Kruskal-Wallis test was used. 
b
 Age as dichotomous variable (under and over median value). 
c Some missing values. 
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Abbreviations: mTOR, mammalian target of rapamycin; SR replication (self-resolved replication). 
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    HIGHLIGHTS     
 
 
 
• We analyze the ability of pretransplant CD8+IFNG+ response to spontaneously clear 
CMV replication in transplant patients. 
 
• Most of the patients do not require antiviral treatment since they prevent or self-
resolve the replication.     
 
• A few patients developed symptomatic replication in spite of having pretransplant 
CD8+IFNG+ response.  
 
• An additional posttransplant IFNG+ response determination might better identify 
patients with spontaneous clearance.  
 
 
 
 
